Lakefront Biotherapeutics NV current report, Q4 FY2018

Business Context and Reporting Period

This Form 6-K is filed by Galapagos NV (not Lakefront Biotherapeutics NV as indicated in metadata) for the month of November 2018. The filing serves to incorporate by reference a press release dated November 23, 2018, which is attached as Exhibit 99.1. The registrant is a foreign private issuer incorporated in Belgium.

Key Financial Metrics

The filing text provided does not contain specific financial data. It does not report revenue, profit, cash flow, margins, debt, or liquidity figures. The document is a procedural filing to distribute a press release rather than a financial statement.

Material Changes

The filing does not detail material changes in financial performance or operations within the text provided. It solely references the issuance of a press release on November 23, 2018, without summarizing its content.

Guidance, Outlook, and Risks

The text does not provide management commentary, guidance, outlook, or specific risk factors. It notes that the information in the attached press release (Exhibit 99.1) is incorporated by reference into various Registration Statements (Forms F-3 and S-8).

Investor Verification Checklist

  • Verify the actual content of the press release dated November 23, 2018 (Exhibit 99.1), as the summary text does not describe the material event.
  • Confirm the registrant name is Galapagos NV, noting a discrepancy with the provided metadata company name.
  • Review the referenced Registration Statements (File Nos. 333-211765, 333-204567, etc.) for context on the incorporated information.
  • Check for subsequent filings if the press release contained material financial updates not detailed in this cover letter.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.